New advances in hematopoietic cell transplantation

Current Opinion in Hematology

Volumn 15, Issue 6, 2008, Pages 549-554

  Petersdorf, Effie W ^a   Hansen, John A ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Cytokine genes; Haplotypes; Human leukocyte antigen; Immune response genes; Microsatellites

Indexed keywords

CYTOKINE; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA DQB1 ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 10; TUMOR NECROSIS FACTOR;

DISEASE ASSOCIATION; DONOR SELECTION; GENE FUNCTION; GENE LOCUS; GENE MAPPING; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HAPLOTYPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HLA SYSTEM; HUMAN; IMMUNE RESPONSE GENE; IMMUNOGENETICS; MAJOR HISTOCOMPATIBILITY COMPLEX; MINOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SEQUENCE ANALYSIS;

GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MAJOR HISTOCOMPATIBILITY COMPLEX; TRANSPLANTATION IMMUNOLOGY;

EID: 55149085208     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e328311891f     Document Type: Review

References (56)

1. Lee SJ, Klein J, Haagenson M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007; 110:4576-4583. This study represents the largest analysis of URD transplants to date. A new finding that single HLA-DQB1 allele mismatches may be tolerated provides a means to extend HCT to DQB1 -mismatched donors when matched donors are not available.
2. Petersdorf EW, Anasetti C, Martin PJ, et al. Limits of HLA mismatching in unrelated hematopoietic cell transplantation. Blood 2004; 104:2976-2980.
3. Flomenberg N, Baxter-Lowe LA, Confer D, et al. Impact of HLA class I and class II high resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplant outcome. Blood 2004; 104:1923-1930.
4. Chalandon Y, Tiercy JM, Schanz U, et al. Impact of high-resolution matching in allogeneic unrelated donor stem cell transplantation In Switzerland. Bone Marrow Transplant 2006; 37:909-916.
5. Yakoub-Agha I, Mesnil F, Kuentz M, et al. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol 2006; 24:5695-5702.
6. Hows JM, Passweg JR, Tichelli A, et al. Comparison of long-term outcomes after allogeneic hematopoietic stem cell transplantation from matched sibling and unrelated donors. Bone Marrow Transplant 2006; 38:799-805.
7. Kennedy-Nasser AA, Leung KS, Mahajan A, et al. Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia. Biol Blood Marrow Transplant 2006; 12:1277-1284.
8. Morishima Y, Sasazuki T, Inoko H, et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood 2002; 99:4200-4206.
9. Morishima Y, Yabe T, Matsuo K, et al. Effects of HLA allele and killer immunoglobulin-like receptor ligand matching on clinical outcome in leukemia patients undergoing transplantation with T-cell-replete marrow from an unrelated donor. Biol Blood Marrow Transplant 2007; 13:315-328.
10. Ferrara GB, Bacigalupo A, Lamparelli T, et al. Bone marrow transplantation from unrelated donors: the impact of mismatches with substitutions at position 116 of the human leukocyte antigen class I heavy chain. Blood 2001; 98:3150-3155.
11. Kawase T, Morishima Y, Matsuo K, et al. High-risk HLA allele mismatch combinations responsible for severe acute graft versus host disease and implication for its molecular mechanism. Blood 2007; 110:2235-2241. The functional importance of donor- recipient mismatching for key polymorphic class I residues extends knowledge on the nature of epitopes involved in peptide-binding repertoire and contact with the T-cell receptor important in defining GVHD risk.
12. Fleischhauer K, Locatelli F, Zecca M, et al. Graft rejection after unrelated donor hematopoietic stem cell transplantation for thalassemia is associated with nonpermissive HLA-DPB1 disparity in host-versus-graft direction. Blood 2006; 107:2984-2992.
13. Horton R, Gibson R, Coggill P, et al. Variation analysis and gene annotation of eight MHC haplotypes: the MHC Haplotype Project, Immunogenetics 2008; 60:1-18. A comprehensive examination of common human HLA haplotypes provides an unprecedented view of the sequence variation within the MHC.
14. Traherne JA, Horton R, Roberts AN, et al. Genetic analysis of completely sequenced disease-associated MHC haplotypes identifies shuffling of segments in recent human history. PLoS Genet 2006; 2:e9.
15. Smith WP, Vu Q, Li SS, et al. Toward understanding MHC disease associations: partial resequencing of 46 distinct HLA haplotypes. Genomics 2006; 87:561-571.
16. Miretti MM, Walsh EC, Ke X, et al. A high-resolution linkage-disequilibrium map of the human major histocompatibility complex and first generation of tag single-nucleotide polymorphisms. Am J Hum Genet 2005; 76:634-646.
17. de Bakker PI, McVean G, Sabeti PC, et al. A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC. Nat Genet 2006; 38:1166-1172.
18. Guo Z, Hood L, Malkki M, Petersdorf EW. Long-range multilocus haplotype phasing of the MHC [erratum appears in Proc Natl Acad Sci U S A 2006; 103:9374]. Proc Natl Acad Sci U S A 2006; 103:6964-6969.
19. Petersdorf EW, Malkki M, Gooley TA, et al. MHC haplotype matching for unrelated hematopoietic cell transplantation. PLoS Med 2007; 4:e8. A long-range phasing technique was applied to define the clinical significance of extended HLA haplotypes in URD HCT. This study demonstrates that undetected MHC region variation may increase the risk of acute GVHD. These results provide a novel approach for mapping genes associated with transplant outcomes.
20. Li S, Kawata H, Katsuyama Y, et al. Association of polymorphic MHC microsatellites with GVHD, survival, and leukemia relapse in unrelated hematopoietic stem cell transplant donor/recipient pairs matched at five HLA loci. Tissue Antigens 2004; 63:362-368.
21. Malkki M, Gooley TA, Horowitz MM, et al. Mapping MHC-resident transplantation determinants. Biol Blood Marrow Transplant 2007; 13:986-995.
22. Gourraud PA, Lamiraux P, El Kadhi N, et al. Inferred HLA haplotype information for donors from hematopoietic stem cells donor registries. Hum Immunol 2005; 66:563-570.
23. Maiers M, Gragert L, Klitz W. High-resolution HLA alleles and haplotypes in the United States population. Hum Immunol 2007; 68:779-788. This analysis provides a comprehensive view of human HLA haplotypes and serves as an important resource for HLA research.
24. Kollman C, Maiers M, Gragert L, et al. Estimation of HLA-A, -B, -DRB1 haplotype frequencies using mixed resolution data from a national registry with selective retyping of volunteers. Hum Immunol 2007; 68:950-958.
25. Muller CR, Ehninger G, Goldmann SF. Gene and haplotype frequencies for the loci hLA-A, hLA-B, and hLA-DR based on over 13,000 German blood donors. Hum Immunol 2003; 64:137-151.
26. Confer DL. The National Marrow Donor Program. Meeting the needs of the medically underserved. Cancer 2001; 91 (Suppl 1):274-278.
27. Schmidt AH, Stahr A, Baier D, et al. Selective recruitment of stem cell donors with rare human leukocyte antigen phenotypes. Bone Marrow Transplant 2007; 40:823-830. Recruitment of the family members of registered URDs with rare alleles and haplotypes provides a means to increase the pool of rare haplotypes in a donor registry. This study by the DKMS registry demonstrates a novel approach for increasing the genetic diversity of a donor pool.
28. Perreault C, Décary F, Brochu S, et al. Minor histocompatibility antigens. Blood 1990; 76:1269-1280.
29. Martin PJ. Increased disparity for minor histocompatibility antigens as a potential cause of increased GVHD risk in marrow transplantation from unrelated donors compared with related donors. Bone Marrow Transplant 1991; 8:217-223.
30. Middleton PG, Taylor PRA, Jackson G, et al. Cytokine gene polymorphisms associating with severe acute graft-versus-host disease in HLA-identical sibling transplants. Blood 1998; 92:3943-3948.
31. Cavet J, Dickinson AM, Norden J, et al. Interferon-gamma and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation. Blood 2001; 98:1594-1600.
32. Socie G, Loiseau P, Tamouza R, et al. Both genetic and clinical factors predict the development of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Transplantation 2001; 72:699-706.
33. Lin M-T, Storer B, Martin PJ, et al. Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med 2003; 349:2201-2210.
34. Bogunia-Kubik K, Polak M, Lange A. TNF polymorphisms are associated with toxic but not with aGVHD complications in the recipients of allogeneic sibling haematopoietic stem cell transplantation. Bone Marrow Transplant 2003; 32:617-622.
35. Mullighan C, Heatley S, Doherty K, et al. Non-HLA immunogenetic polymorphisms and the risk of complications after allogeneic hemopoietic stemcell transplantation. Transplantation 2004; 27:587-596.
36. Keen LJ, Defor TE, Bidwell JL, et al. Interleukin-10 and tumor necrosis factor alpha region haplotypes predict transplant-related mortality after unrelated donor stem cell transplantation. Blood 2004; 103:3599-3602.
37. Cavet J, Middleton PG, Segall M, et al. Recipient tumor necrosis factor-alpha and interleukin-10 gene polymorphisms associate with early mortality and acute graft-versus-host disease severity in HLA-matched sibling bone marrow transplants. Blood 1999; 94:3941-3946.
38. Takahashi H, Furukawa T, Hashimoto S, et al. Contribution of TNF-alpha and IL-10 gene polymorphisms to graft-versus-host disease following allohematopoietic stem cell transplantation. Bone Marrow Transplant 2000; 26: 1317-1323.
39. Rocha V, Franco RF, Porcher R, et al. Host defense and inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone marrow transplantation. Blood 2002; 100:3908-3918.
40. Karabon L, Wysoczanska B, Bogunia-Kubik K, et al. IL-6 and IL-10 promoter gene polymorphisms of patients and donors of allogeneic sibling hematopoietic stem cell transplants associate with the risk of acute graft-versus-host disease. Hum Immunol 2005; 66:700-710.
41. Kim DH, Lee NY, Sohn SK, et al. IL-10 promoter gene polymorphism associated with the occurrence of chronic QVHD and its clinical course during systemic immunosuppressive treatment for chronic GVHD after allogeneic peripheral blood stem cell transplantation. Transplantation 2005; 79:1615-1622.
42. Bettens F, Passweg J, Gratwohl A, et al. Association of TNFd and IL-10 polymorphisms with mortality in unrelated hematopoietic stem cell transplantation. Transplantation 2006; 81:1261-1267.
43. Lin M-T, Storer B, Martin PJ, et al. Genetic variation in the IL-10 pathway modulates severity of acute graft-versus-host disease following hematopoietic cell transplantation: synergism between IL-10 genotype of patient and IL-10 receptor b genotype of donor. Blood 2005; 106:3995-4001.
44. Cullup H, Dickinson AM, Jackson GH, et al. Donor interleukin 1 receptor antagonist genotype associated with acute graft-versus-host disease in human leucocyte antigen-matched sibling allogeneic transplants. Br J Haematol 2001; 113:807-813.
45. MacMillan ML, Radloff GA, Kiffmeyer WR, et al. High-producer interleukin-2 genotype increases risk for acute graft-versus-host disease after unrelated donor bone marrow transplantation. Transplantation 2003; 76:1758-1762.
46. MacMillan ML, Radloff GA, Defor TE, et al. Interleukin-1 genotype and outcome of unrelated donor bone marrow transplantation. Br J Haematol 2003; 121:597-604.
47. Stark GL, Dickinson AM, Jackson GH, et al. Tumour necrosis factor receptor type II 196M/R genotype correlates with circulating soluble receptor levels in normal subjects and with gratt-versus-host disease after sibling allogeneic bone marrow transplantation. Transplantation 2003; 76:1742-1749.
48. Holler E, Rogler G, Herfarth H, et al. Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GVHD following allogeneic stem cell transplantation. Blood 2004; 104:889-894.
49. Seo KW, Kim DH, Sohn SK, et al. Protective role of interleukin-10 promoter gene polymorphism in the pathogenesis of invasive pulmonary aspergillosis after allogeneic stem cell transplantation. Bone Marrow Transplant 2005; 36:1089-1095.
50. Bogunia-Kubik K, Mlynarczewska A, Jaskula E, Lange A. The presence of IFNG 3/3 genotype in the recipient associates with increased risk for Epstein-Barr virus reactivation after allogeneic haematopoietic stem cell transplantation. Br J Haematol 2006; 132:326-332.
51. Holler E, Rogler G, Brenmoehl J, et al. Prognostic significance of NOD2/CARD15 variants in HLA-identical sibling hematopoietic stem cell transplantation: effect on long term outcome is confirmed in 2 independent cohorts and may be modulated by the type of gastrointestinal decontamination. Blood 2006; 107:4189-4193.
52. Shamim Z, Ryder LP, Heilmann C, et al. Genetic polymorphisms in the genes encoding human interleukin-7 receptor-alpha: prognostic significance in allogeneic stem cell transplantation. Bone Marrow Transplant 2006; 37: 485-491.
53. Perez-Garcia A, de la Cámara R, Roman-Gomez J, et al. CTLA-4 polymorphisms and clinical outcome after allogeneic stem cell transplantation from HLA-identical sibling donors. Blood 2007; 110:461-467.
54. Mullally A, Ritz J. Beyond HLA: the significance of genomic variation for allogeneic hematopoietic stem cell transplantation. Blood 2007; 109:1355-1362. The authors illustrate how emerging technologies are rapidly expanding knowledge of the human genome, and how structural variation and deletions can uniquely contribute to disparity for mHAs.
55. Mullighan CG, Bardy PG. New directions in the genomics of allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13:127-144. This recent review provides a critical overview that goes beyond the scope of this Current Opinion article and comprehensively summarizes known mHAs and non-MHC IRG variants that have been reported associated with HCT outcome.
56. Dickinson AM. Risk assessment in haematopoietic stem cell transplantation: pretransplant patient and donor factors: non-HLA genetics [Review]. Bailliere's Best Pract Clin Haematol 2007; 20:189-207.